Allon CSO presents pre-clinical data on compound to protect brain cells
17-Mar-2005 -
Allon Therapeutics Inc., The Neuro Protection Company(TM), has presented pre-clinical data that helps explain how the company's proprietary lead compound AL-108 protects brain cells from degenerative diseases.
Dr. Illana Gozes, Chief Scientific Officer of Allon, said , that AL-108 was shown to ...
Alzheimer's disease
amino acid derivatives
BrainCells
+9